{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:31:35Z","timestamp":1761154295277,"version":"3.41.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1997,7,1]],"date-time":"1997-07-01T00:00:00Z","timestamp":867715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1997,7,1]],"date-time":"1997-07-01T00:00:00Z","timestamp":867715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[1997,7]]},"DOI":"10.1023\/a:1007701606758","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T11:08:11Z","timestamp":1040555291000},"page":"465-470","source":"Crossref","is-referenced-by-count":10,"title":["Quality of Life Comparison Between Bisoprolol and Nifedipine Retard in Hypertension"],"prefix":"10.1007","volume":"11","author":[{"given":"Jan N.J.M.","family":"de Hoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floris H.M.","family":"Vanmolkot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis L.M.","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc M.A.B.","family":"Van Bortel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"145424_CR1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/00004872-199309000-00004","volume":"11","author":"Guidelines Sub-Commitee.","year":"1993","unstructured":"Guidelines Sub-Commitee. 1993 Guidelines for the management of mild hypertension: Memorandum from a World Health Organization\/International Society of hypertension meeting. J Hypertens 1993;11:905\u2013918.","journal-title":"J Hypertens"},{"key":"145424_CR2","first-page":"129","volume":"1","author":"LA McDonald","year":"1985","unstructured":"McDonald LA, Sackett DL, Haynes RB, Taylor W. Hypertension: The effects of labelling on behaviour. Quality of life and cardiovascular care 1985;1:129\u2013139.","journal-title":"Quality of life and cardiovascular care"},{"key":"145424_CR3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/0002-8703(88)90561-3","volume":"116","author":"NK. Wenger","year":"1988","unstructured":"Wenger NK. Quality of life issues in hypertension: Consequences of diagnosis and considerations in management. Am Heart J 1988;116:628\u2013632.","journal-title":"Am Heart J"},{"issue":"Suppl6","key":"145424_CR4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199212071-00001","volume":"20","author":"KO. Stumpe","year":"1992","unstructured":"Stumpe KO. Antihypertensive therapy: New strategies beyond blood pressure control. J Cardiovasc Pharmacol 1992;20(Suppl 6):S1\u2013S4.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl3","key":"145424_CR5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/clc.4960181504","volume":"18","author":"N. Bittar","year":"1995","unstructured":"Bittar N. Maintaining long-term control of blood pressure: The role of improved compliance. Clin Cardiol 1995;18(Suppl 3):12\u201316.","journal-title":"Clin Cardiol"},{"key":"145424_CR6","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/00004872-199210120-00001","volume":"10","author":"P Hjemdahl","year":"1992","unstructured":"Hjemdahl P, Wiklund IK. Quality of life on antihypertensive drug therapy: Scientific end-point or marketing exercise? J Hypertens 1992;10:1437\u20131446.","journal-title":"J Hypertens"},{"key":"145424_CR7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1056\/NEJM199603283341306","volume":"334","author":"MA Testa","year":"1996","unstructured":"Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996;334:835\u2013840.","journal-title":"N Engl J Med"},{"key":"145424_CR8","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM198606263142602","volume":"314","author":"SH Croog","year":"1986","unstructured":"Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657\u20131664.","journal-title":"N Engl J Med"},{"key":"145424_CR9","first-page":"217","volume":"4","author":"SS Steiner","year":"1990","unstructured":"Steiner SS, Friedhoff AJ, Wilson BL, Wecker JR, Santo JP. Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol. J Hum Hypertens 1990;4:217\u2013225.","journal-title":"J Hum Hypertens"},{"key":"145424_CR10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.HYP.19.6.499","volume":"19","author":"AE Fletcher","year":"1992","unstructured":"Fletcher AE, Bulpitt CJ, Chase DM, et al. Quality of life with three antihypertensive treatments: cilazapril, atenolol, nifedipine. Hypertension 1992;19:499\u2013507.","journal-title":"Hypertension"},{"key":"145424_CR11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00004872-199005000-00011","volume":"8","author":"AE Fletcher","year":"1990","unstructured":"Fletcher AE, Bulpitt CJ, Hawkins CM, et al. Quality of life on antihypertensive therapy: A randomized double-blind controlled trial of captopril and atenolol. J Hypertens 1990;8:463\u2013466.","journal-title":"J Hypertens"},{"key":"145424_CR12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/ajh\/5.3.125","volume":"5","author":"JA Beto","year":"1992","unstructured":"Beto JA, Bansal VK. Quality of life in treatment of hypertension. A metaanalysis of clinical trials. Am J Hypertens 1992;5:125\u2013133.","journal-title":"Am J Hypertens"},{"key":"145424_CR13","first-page":"750","volume":"20","author":"JGS Breed","year":"1992","unstructured":"Breed JGS, Ciampricotti R, Tromp GP, Valster FA, Lageweg E, Van Bortel LMAB. Quality of life perception during antihypertensive treatment: A comparative study of bisoprolol and enalapril. J Cardiovasc Pharmacol 1992;20:750\u2013755.","journal-title":"J Cardiovasc Pharmacol"},{"key":"145424_CR14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/clpt.1990.174","volume":"48","author":"JA Blumenthal","year":"1990","unstructured":"Blumenthal JA, Ekelund L-G, Emery CF. Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril. Clin Pharmacol Ther 1990;48:447\u2013454.","journal-title":"Clin Pharmacol Ther"},{"key":"145424_CR15","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00004872-199211000-00014","volume":"10","author":"AJ Palmer","year":"1992","unstructured":"Palmer AJ, Fletcher AE, Rudge PJ, Andrews CD, Callaghan TS, Bulpitt CJ. Quality of life in hypertensives treated with atenolol or captopril: A double-blind crossover trial. J Hypertens 1992;10:1409\u20131416.","journal-title":"J Hypertens"},{"key":"145424_CR16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1742-1241.1992.tb10282.x","volume":"46","author":"JM. Cruikshank","year":"1992","unstructured":"Cruikshank JM. Beta blockers and quality of life. Br J Clin Pract 1992;46:34\u201338.","journal-title":"Br J Clin Pract"},{"key":"145424_CR17","first-page":"1097","volume":"9","author":"I Os","year":"1991","unstructured":"Os I, Bratland B, Dahl\u00f8f B, Gisholt K, Syvertsen J, Tretli S. Lisinopril or nifedipine in essential hypertension? A Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. J Hypertens 1991;9:1097\u20131104.","journal-title":"J Hypertens"},{"key":"145424_CR18","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/00004872-199509000-00018","volume":"13","author":"JP Boissel","year":"1995","unstructured":"Boissel JP, Collet JP, Lion L, et al. A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: Field trial in general practice. J Hypertens 1995;13:1059\u20131067.","journal-title":"J Hypertens"},{"key":"145424_CR19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/ajh\/4.4.363","volume":"4","author":"MA Testa","year":"1991","unstructured":"Testa MA, Hollenberg NK, Anderson RB, Williams GH. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. Am J Hypertens 1991;4:363\u2013373.","journal-title":"Am J Hypertens"},{"key":"145424_CR20","first-page":"125","volume":"3","author":"AE Fletcher","year":"1989","unstructured":"Fletcher AE, Chester PC, Hawkins CMA, Latham AN, Pike LA, Bulpitt CJ. The effects of verapamil and propranolol on quality of life in hypertension. J Hum Hypertens 1989;3:125\u2013130.","journal-title":"J Hum Hypertens"},{"key":"145424_CR21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2125.1990.tb03785.x","volume":"30","author":"A Palmer","year":"1990","unstructured":"Palmer A, Fletcher A, Hamilton G, Muriss S, Bulpitt C. A comparison of verapamil and nifedipine on quality of life. Br J Clin Pharmacol 1990;30:365\u201370.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl1","key":"145424_CR22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003495-199200441-00026","volume":"44","author":"A Fletcher","year":"1992","unstructured":"Fletcher A, Bulpitt C. Quality of life in treatment of hypertension. The effect of calcium antagonists. Drugs 1992;44(Suppl 1):135\u201340.","journal-title":"Drugs"},{"issue":"Suppl11","key":"145424_CR23","first-page":"S46","volume":"8","author":"B Kr\u00e4mer","year":"1986","unstructured":"Kr\u00e4mer B, Balser J, Stubbig K, Kr\u00e4mer G, K\u00fcbler W. Comparison of bisoprolol with other \u03b2-adrenoceptor blocking drugs. J Cardiovasc Pharmacol 1986;8(Suppl 11):S46\u2013S57.","journal-title":"J Cardiovasc Pharmacol"},{"key":"145424_CR24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-2125.1990.tb03784.x","volume":"30","author":"CJ Bulpitt","year":"1990","unstructured":"Bulpitt CJ, Fletcher AE. The measurement of quality of life in hypertensive patients: A practical approach. Br J Clin Pharmacol 1990;30:353\u2013364.","journal-title":"Br J Clin Pharmacol"},{"key":"145424_CR25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2307\/2556170","volume":"28","author":"GG. Koch","year":"1972","unstructured":"Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972;28:577\u2013584.","journal-title":"Biometrics"},{"key":"145424_CR26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/009286159102500311","volume":"25","author":"D Gillings","year":"1991","unstructured":"Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inform J 1991;25:411\u2013424.","journal-title":"Drug Inform J"},{"issue":"Suppl1","key":"145424_CR27","first-page":"S46","volume":"7","author":"S Jern","year":"1993","unstructured":"Jern S, Zanchetti A. The issue of quality of life in antihypertensive therapy. J Hum Hypertens 1993;7(Suppl 1):S46\u2013S49.","journal-title":"J Hum Hypertens"},{"key":"145424_CR28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00053441","volume":"4","author":"ST McCarthy","year":"1990","unstructured":"McCarthy ST, McCarthy GL, John SM, Gould SE. A placebo-controlled cross-over study of ketanserin in elderly hypertensive patients. Cardiovasc Drugs Ther 1990;4:115\u2013117.","journal-title":"Cardiovasc Drugs Ther"},{"key":"145424_CR29","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/00005344-199306000-00002","volume":"21","author":"LMAB Van Bortel","year":"1993","unstructured":"Van Bortel LMAB, Breed JGS, Joosten J, Kragten JA, Lustermans FAT, Mooij JMV. Nebivolol in hypertension: A double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993;21:856\u2013862.","journal-title":"J Cardiovasc Pharmacol"},{"key":"145424_CR30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.1993.03510060059034","volume":"270","author":"JD Neaton","year":"1993","unstructured":"Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. Final results. JAMA 1993;270:713\u2013724.","journal-title":"JAMA"},{"key":"145424_CR31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/jama.1986.03370030077031","volume":"255","author":"J Avorn","year":"1986","unstructured":"Avorn J, Everitt DE, Weiss S. Increased anti-depressant use in patients prescribed beta-blockers. JAMA 1986;255:357\u2013360.","journal-title":"JAMA"},{"issue":"SupplVI","key":"145424_CR32","first-page":"VI108","volume":"84","author":"C Dahl\u00f6f","year":"1991","unstructured":"Dahl\u00f6f C, Dimen\u00e4s E, Kendall M, Wilklund I. Quality of life in cardiovascular diseases. Emphasis on \u03b2-blocker treatment. Circulation 1991;84(Suppl VI):VI108\u2013VI118.","journal-title":"Circulation"},{"key":"145424_CR33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/00019053-199508060-00006","volume":"8","author":"LMAB Van Bortel","year":"1995","unstructured":"Van Bortel LMAB, Ament AJHA. Selective versus nonselective \u03b2-adrenoceptor antagonists in hypertension. Pharmacoeconomics 1995;8:513\u2013523.","journal-title":"Pharmacoeconomics"},{"key":"145424_CR34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00543714","volume":"Suppl28","author":"A. Westerlund","year":"1985","unstructured":"Westerlund A. Central nervous system side-effects with hydrophilic and lipophilic beta-blockers. Eur J Clin Pharmacol 1985(Suppl 28):73\u201376.","journal-title":"Eur J Clin Pharmacol"},{"key":"145424_CR35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/clpt.1987.5","volume":"41","author":"CH Kleinbloesem","year":"1987","unstructured":"Kleinbloesem CH, van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987;41:26\u201330.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1007701606758.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1007701606758\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1007701606758.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T19:09:21Z","timestamp":1751051361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1007701606758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["145424"],"URL":"https:\/\/doi.org\/10.1023\/a:1007701606758","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[1997,7]]}}}